March 22, 2026 07:39 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Mamata unveils TMC candidate list for Bengal polls; to face Suvendu in Bhabanipur | ‘Not a one-day battle for me’: Mamata Banerjee on facing Suvendu Adhikari in Bhabanipur | Mamata vs Suvendu: Bhabanipur set for high-voltage showdown | Barbaric: India condemns Pakistani airstrike on Kabul hospital | Middle East conflict: Israel says it killed key Iranian commander during overnight strike | Middle East on edge: Kataeb Hezbollah commander Abu Ali al-Askari killed | Middle East on edge: Kataeb Hezbollah commander Abu Ali al-Askari killed | Afghanistan claims Pakistani airstrike on Kabul hospital left 400 killed, Islamabad denies | ECI orders major reshuffle in Bengal police brass a day after poll announcement | 10 patients killed in fire at SCB Medical College Hospital in Cuttack; staff injured
South Korea COVID-19
Image: Wallpaper Cave

South Korea approves first oral Covid pill treatment

| @indiablooms | Dec 27, 2021, at 10:26 pm

Seoul/UNI/Sputnik: South Korea’s Ministry of Food and Drug Safety on Monday approved Pfizer’s oral antiviral pill, the first one to treat Covid-19 in the country, after a panel of experts reviewed its safety and efficiency, national media said.

Pfizer’s Paxlovid is a pill treatment of mild-to-moderate Covid-19 cases for people 12 years of age and older weighing at least 88 pounds with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe Covid-19, including hospitalization or death, according to the US Food and Drug Association.

Paxlovid is not a substitute for vaccination for those whom Covid-19 vaccination and a booster shot are advised. It is administered by prescription only.

Paxlovid consists of three tablets taken together orally twice a day for five days.

The treatment should be administered as soon as possible after diagnosis of Covid-19 and within five days of symptom onset, according to Pfizer.

Paxlovid is believed to reduce the risk of hospitalisation or death among patients at high risk of severe illness by 88 percent.

Currently, South Korea uses Remdesivir and Rekirona intravenous injections to treat critical cases and to reduce the risk of infection progressing to severe cases, respectively.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.